Roberts M Scot 4

What Happened Roberts M. Scot, Chief Scientific Officer of Altimmune (ALT), had 15,850 restricted stock units (RSUs vest) convert into common shares on January 27, 2026. Of those shares, 4,748 were surrendered to the company to satisfy tax withholding obligations at $6.18 per share (total withholding value $29,343). The net result was 11,102 shares retained by the insider. This was an award/vesting event (not an open-market sale or purchase).

Key Details

• Transaction date: January 27, 2026; Form 4 filed January 29, 2026 (timely filing).
• Vesting/Conversion: 15,850 RSUs converted to 15,850 common shares (reported as derivative exercise/conversion, code M) with $0 exercise price.
• Tax withholding: 4,748 shares surrendered (code F) at $6.18 per share = $29,343.
• Net shares retained from this vesting: 11,102.
• Shares owned following the reported transactions: not specified in the filing.
• Footnotes: RSUs represent a contingent right to one share when vested (F1); shares were surrendered solely to cover taxes (F2); RSUs vest in substantially equal annual installments over 4 years from Jan 27, 2025 and have no expiration (F3).
• Transaction codes: M = exercise/conversion of derivative (RSU conversion); F = shares withheld for tax withholding.

Context This was a routine vesting of RSUs rather than a market buy or sell; withholding shares for taxes is a common administrative step and does not by itself indicate a change in insider sentiment. The filing appears timely (filed within the required two business days).